<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease - Welsh, EJ - 2013 | Cochrane Library</title> <meta content="Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease - Welsh, EJ - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007891.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease - Welsh, EJ - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007891.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007891.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease" name="citation_title"/> <meta content="Emma J Welsh" name="citation_author"/> <meta content="St George's University of London" name="citation_author_institution"/> <meta content="ewelsh@sgul.ac.uk" name="citation_author_email"/> <meta content="Christopher J Cates" name="citation_author"/> <meta content="St George's University of London" name="citation_author_institution"/> <meta content="Phillippa Poole" name="citation_author"/> <meta content="University of Auckland" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD007891.pub3" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/05/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007891.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007891.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007891.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Adrenergic beta‐2 Receptor Agonists [*administration &amp; dosage]; Albuterol [administration &amp; dosage, *analogs &amp; derivatives]; Androstadienes [*administration &amp; dosage]; Bronchodilator Agents [*administration &amp; dosage]; Drug Therapy, Combination [methods]; Fluticasone; Patient Dropouts [statistics &amp; numerical data]; Pneumonia [drug therapy]; Pulmonary Disease, Chronic Obstructive [*drug therapy, mortality]; Salmeterol Xinafoate; Scopolamine Derivatives [*administration &amp; dosage]; Tiotropium Bromide" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007891.pub3&amp;doi=10.1002/14651858.CD007891.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="xcg9958b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007891\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007891\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007891.pub3",title:"Combination inhaled steroid and long\\u2010acting beta2\\u2010agonist versus tiotropium for chronic obstructive pulmonary disease",firstPublishedDate:"May 31, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007891.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007891.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007891.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007891.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007891.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007891.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007891.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007891.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007891.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007891.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>947 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007891.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/full#CD007891-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/full#CD007891-sec-0074"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/full#CD007891-sec-0015"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/full#CD007891-sec-0019"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/full#CD007891-sec-0020"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/full#CD007891-sec-0042"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/full#CD007891-sec-0067"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/appendices#CD007891-sec-0079"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/table_n/CD007891StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/table_n/CD007891StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Combination inhaled steroid and long‐acting beta2‐agonist versus tiotropium for chronic obstructive pulmonary disease </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/information#CD007891-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Emma J Welsh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/information#CD007891-cr-0003">Christopher J Cates</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007891.pub3/information#CD007891-cr-0004">Phillippa Poole</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/information/en#CD007891-sec-0095">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 May 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007891.pub3">https://doi.org/10.1002/14651858.CD007891.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007891-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007891-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007891-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007891-abs-0005">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007891-abs-0001" lang="en"> <section id="CD007891-sec-0001"> <h3 class="title" id="CD007891-sec-0001">Background</h3> <p>Combination therapy (inhaled corticosteroids and long‐acting beta<sub>2</sub>‐agonists) and tiotropium are both used in the treatment of chronic obstructive pulmonary disease (COPD). There is uncertainty about the relative benefits and harms of these treatments. </p> </section> <section id="CD007891-sec-0002"> <h3 class="title" id="CD007891-sec-0002">Objectives</h3> <p>To compare the relative effects of inhaled combination therapy and tiotropium on markers of exacerbations, symptoms, quality of life, lung function, pneumonia and serious adverse events in patients with chronic obstructive pulmonary disease. </p> </section> <section id="CD007891-sec-0003"> <h3 class="title" id="CD007891-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group Specialised Register of trials (November 2012) and reference lists of articles. We also contacted authors of the studies. </p> </section> <section id="CD007891-sec-0004"> <h3 class="title" id="CD007891-sec-0004">Selection criteria</h3> <p>We included only parallel, randomised controlled trials comparing inhaled combination corticosteroid and long‐acting beta<sub>2</sub>‐agonist against inhaled tiotropium bromide. </p> </section> <section id="CD007891-sec-0005"> <h3 class="title" id="CD007891-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed trials for inclusion and then extracted data on trial quality and outcome results. We contacted study authors for additional information. We resolved discrepancies through discussion. </p> </section> <section id="CD007891-sec-0006"> <h3 class="title" id="CD007891-sec-0006">Main results</h3> <p>One large, two‐year trial (INSPIRE) and two smaller, shorter trials on a total of 1528 participants were found. The results from these trials were not pooled. The number of withdrawals from each arm of the <a href="http://INSPIRE" target="_blank">INSPIRE</a> trial was large and imbalanced and outcome data were not collected for patients who withdrew, raising concerns about the reliability of data from this study. </p> <p>In <a href="http://INSPIRE" target="_blank">INSPIRE</a>, there were more deaths on tiotropium than on fluticasone/salmeterol (Peto odds ratio (OR) 0.55; 95% confidence interval (CI) 0.33 to 0.93). This was a statistically significant difference, however the number of withdrawals from each of the arms was 11 times larger than the observed number of deaths for participants on fluticasone/salmeterol and seven times larger for participants on tiotropium. There were more all‐cause hospital admissions in patients on fluticasone/salmeterol than those on tiotropium in <a href="http://INSPIRE" target="_blank">INSPIRE</a> (Peto OR 1.32; 95% CI 1.04 to 1.67). There was no statistically significant difference in hospital admissions due to exacerbations, the primary outcome of <a href="http://INSPIRE" target="_blank">INSPIRE</a>. There was no significant difference in exacerbations in patients on fluticasone/salmeterol compared to tiotropium when compared as either an odds ratio or a rate ratio (mean number of exacerbations per patient per year). Exacerbations requiring treatment with oral corticosteroids were less frequent in patients on fluticasone/salmeterol (rate ratio 0.81; 95% CI 0.67 to 0.99). Conversely exacerbations requiring treatment with antibiotics were more frequent in patients treated with fluticasone/salmeterol (rate ratio 1.19; 95% CI 1.02 to 1.38). There were more cases of pneumonia in patients on fluticasone/salmeterol than in those on tiotropium (Peto OR 2.13; 95% CI 1.33 to 3.40). Confidence intervals for these outcomes do not reflect the additional uncertainty arising from unknown outcome data for patients who withdrew. </p> </section> <section id="CD007891-sec-0007"> <h3 class="title" id="CD007891-sec-0007">Authors' conclusions</h3> <p>Since the proportion of missing outcome data compared to the observed outcome data is enough to induce a clinically relevant bias in the intervention effect, the relative efficacy and safety of combined inhalers and tiotropium remains uncertain. Further large, long‐term randomised controlled trials comparing combination therapy to tiotropium are required, including adequate follow‐up of all participants randomised (similar to the procedures undertaken in TORCH and UPLIFT). Additional studies comparing alternative inhaled long‐acting beta<sub>2</sub>‐agonist/steroid combination therapies with tiotropium are also required. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007891-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007891-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007891-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007891-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007891-abs-0003" lang="en"> <h3>Combined inhalers compared to tiotropium inhalers for the treatment of chronic obstructive pulmonary disease </h3> <p>Chronic obstructive pulmonary disease (COPD) is a general term referring to chronic bronchitis and emphysema, or both. COPD occurs when airflow to the lungs is restricted. Symptoms include cough and breathlessness and inhalers are commonly used to prevent and relieve these symptoms. COPD is usually caused by smoking and the best way to improve symptoms is to give up smoking. </p> <p>COPD trials lasting longer than six months often have large numbers of people leaving the trial early. In INSPIRE, the largest trial in our review, comparing fluticasone/salmeterol to tiotropium, there were seven to 11 times more people leaving the trial early than the number who died; a number that swamps the death rate. Therefore we felt unable to draw a reliable conclusion as to which treatment has the lowest mortality rate. This uncertainty also left us unable to reliably say which drug was better in terms of reducing COPD exacerbations, hospitalisations and serious adverse events or improving quality of life and health status. </p> <p>More information about COPD and explanations of terms used in this summary can be found <a href="http://www.patient.co.uk/health/chronic-obstructive-pulmonary-disease" target="_blank">here</a>. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007891-sec-0074" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007891-sec-0074"></div> <h3 class="title" id="CD007891-sec-0075">Implications for practice</h3> <section id="CD007891-sec-0075"> <p><a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> had a high and unbalanced withdrawal rate. The proportion of missing outcome data compared to the observed outcome data is enough to induce a clinically relevant bias in the intervention effect. The relative efficacy and safety of combined inhalers and tiotropium remains uncertain. </p> </section> <h3 class="title" id="CD007891-sec-0076">Implications for research</h3> <section id="CD007891-sec-0076"> <p>Further large, long‐term randomised controlled trials comparing combination therapy to tiotropium are required, including follow‐up of all participants randomised (similar to TORCH and UPLIFT). Additional studies comparing alternative inhaled long‐acting beta<sub>2</sub>‐agonist/steroid combination therapies with tiotropium are also required. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007891-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007891-sec-0015"></div> <section id="CD007891-sec-0016"> <h3 class="title" id="CD007891-sec-0016">Description of the condition</h3> <p>Chronic obstructive pulmonary disease (COPD) is characterised by chronic airflow limitation and limited response to short‐acting beta<sub>2</sub>‐agonists, and is associated with a smoking history (<a href="./references#CD007891-bbs2-0034" title="Global Initiative for Chronic Obstructive Lung Disease. http://www.goldcopd.com (accessed 18 February 2009). ">GOLD</a>). Symptoms of COPD include breathlessness and impaired exercise capacity. There are a number of commonly used pharmacological treatments in COPD management including inhaled short‐acting beta‐agonists (SABA), long‐acting beta<sub>2</sub>‐agonists (LABA) (<a href="./references#CD007891-bbs2-0026" title="AppletonS , PooleP , SmithB , VealeA , LassersonTJ , ChanMMK , et al. Long‐acting beta2‐agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD001104.pub2] ">Appleton 2006a</a>), inhaled corticosteroids (ICS) (<a href="./references#CD007891-bbs2-0056" title="YangIA , ClarkeMS , SimEHA , FongKM . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3] ">Yang 2012</a>) and anticholinergics such as tiotropium (<a href="./references#CD007891-bbs2-0040" title="KarnerC , ChongJ , PooleP . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD009285.pub2] ">Karner 2012a</a>) and ipratropium bromide (<a href="./references#CD007891-bbs2-0027" title="AppletonS , JonesT , PooleP , PilottoL , AdamsR , LassersonTJ , et al. Ipratropium bromide versus short acting beta‐2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD001387.pub2] ">Appleton 2006b</a>; <a href="./references#CD007891-bbs2-0028" title="AppletonS , JonesT , PooleP , LassersonTJ , AdamsR , SmithB , et al. Ipratropium bromide versus long‐acting beta‐2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD006101] ">Appleton 2006c</a>). Self management education and pulmonary rehabilitation should accompany these pharmacological interventions (<a href="./references#CD007891-bbs2-0033" title="EffingT , MonninkhofEEM , van derValkPP , ZielhuisGGA , WaltersEH , van derPalenJJ . Self‐management education for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD002990.pub2] ">Effing 2007</a>; <a href="./references#CD007891-bbs2-0043" title="LacasseY , GoldsteinR , LassersonTJ , MartinS . Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2006, Issue 4. [DOI: 10.1002/14651858.CD003793.pub2] ">Lacasse 2006</a>). </p> </section> <section id="CD007891-sec-0017"> <h3 class="title" id="CD007891-sec-0017">Description of the intervention</h3> <p>Combination therapy is a maintenance inhaler that delivers an inhaled corticosteroid and a long‐acting beta‐agonist concurrently at the same dose. Combination therapy is currently available as combination fluticasone and salmeterol (marketed as Seretide or Advair, GlaxoSmithKline) and budesonide and formoterol (marketed as Symbicort, AstraZeneca). Both combination products are licensed for use in COPD at the highest doses of ICS (daily dose fluticasone 1000 μg and budesonide 800 μg). Inhaled corticosteroids are anti‐inflammatories and long‐acting beta‐agonists cause smooth muscle relaxation resulting in bronchodilation. </p> <p>Tiotropium bromide (marketed as 'Spiriva', Boehringer Ingelheim) is an inhaled long‐acting anticholinergic agent, and has gained widespread acceptance as a maintenance therapy in COPD (<a href="./references#CD007891-bbs2-0029" title="BarrRG , BourbeauJ , CamargoCA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>; <a href="./references#CD007891-bbs2-0034" title="Global Initiative for Chronic Obstructive Lung Disease. http://www.goldcopd.com (accessed 18 February 2009). ">GOLD</a>; <a href="./references#CD007891-bbs2-0055" title="TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(15):1543‐54. ">UPLIFT</a>). Tiotropium is a long‐acting anticholinergic agent that targets bronchospasm in COPD by relaxing airway smooth muscle. </p> </section> <section id="CD007891-sec-0018"> <h3 class="title" id="CD007891-sec-0018">Why it is important to do this review</h3> <p>Both tiotropium and combination inhalers have been shown to improve key clinical indicators of disease in clinical trials against placebo. </p> <p>Combination therapy has been shown to reduce exacerbations and mortality, and to improve health status compared to placebo (<a href="./references#CD007891-bbs2-0044" title="NanniniLJ , CatesCJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003794.pub3] ">Nannini 2007a</a>). Inhaled corticosteroids alone reduce the mean rate of COPD exacerbations and the decline in quality of life although do not have an effect on lung function (<a href="./references#CD007891-bbs2-0056" title="YangIA , ClarkeMS , SimEHA , FongKM . Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD002991.pub3] ">Yang 2012</a>). Long‐acting beta‐agonists have also been shown to reduce exacerbations and improve lung function (<a href="./references#CD007891-bbs2-0026" title="AppletonS , PooleP , SmithB , VealeA , LassersonTJ , ChanMMK , et al. Long‐acting beta2‐agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD001104.pub2] ">Appleton 2006a</a>). The effects of combination treatment against component monotherapy are more variable (<a href="./references#CD007891-bbs2-0046" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2] ">Nannini 2012</a>; <a href="./references#CD007891-bbs2-0045" title="NanniniLJ , CatesCJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD006826] ">Nannini 2007b</a>). However, concerns have been raised about the risk of pneumonia associated with ICS in COPD patients (<a href="./references#CD007891-bbs2-0050" title="SinghS , AminAV , LokeYK . Long‐term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease. Archives of Internal Medicine2009;169(3):219‐29. ">Singh 2009</a>). </p> <p>Benefits of tiotropium in comparison with placebo include reduced exacerbations and related hospital admissions, and improvements in quality of life and lung function (<a href="./references#CD007891-bbs2-0029" title="BarrRG , BourbeauJ , CamargoCA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>; <a href="./references#CD007891-bbs2-0055" title="TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(15):1543‐54. ">UPLIFT</a>). However, in the UPLIFT trial conducted over four years tiotropium did not slow the rate of decline in FEV<sub>1</sub> (forced expiratory volume in one second) compared with placebo (<a href="./references#CD007891-bbs2-0055" title="TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(15):1543‐54. ">UPLIFT</a>). Concerns that inhaled anticholinergics increase the long‐term risk of major cardiovascular events in COPD have been raised (<a href="./references#CD007891-bbs2-0049" title="SinghS , LokeYK , FurbergCD . Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta‐analysis. JAMA2008;300(12):1439‐50. ">Singh 2008b</a>), but this was not found in <a href="./references#CD007891-bbs2-0055" title="TashkinDP , CelliB , SennS , BurkhartD , KestenS , MenjogeS , et al. A 4‐year trial of tiotropium in chronic obstructive pulmonary disease. New England Journal of Medicine2008;359(15):1543‐54. ">UPLIFT</a>. </p> <p>This leaves clinicians and patients facing uncertainty as to the relative merits of these treatments, and how the side effect profiles of each compare. </p> <p>Other relevant Cochrane reviews compare tiotropium with placebo (<a href="./references#CD007891-bbs2-0040" title="KarnerC , ChongJ , PooleP . Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD009285.pub2] ">Karner 2012a</a>), tiotropium with LABA (<a href="./references#CD007891-bbs2-0031" title="ChongJ , KarnerC , PooleP . Tiotropium versus long‐acting beta‐agonists for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD009157.pub2] ">Chong 2012</a>), tiotropium and LABA with either drug as monotherapy (<a href="./references#CD007891-bbs2-0039" title="KarnerC , CatesCJ . Long‐acting beta2‐agonist in addition to tiotropium versus either tiotropium or long‐acting beta2‐agonist alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD008989.pub2] ">Karner 2012</a>), inhaled steroid and LABA and tiotropium compared to LABA and tiotropium (<a href="./references#CD007891-bbs2-0038" title="KarnerC , CatesCJ . The effect of adding inhaled corticosteroids to tiotropium and long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 9. [DOI: 10.1002/14651858.CD009039.pub2] ">Karner 2011a</a>), and inhaled steroids with LABA (<a href="./references#CD007891-bbs2-0051" title="SpencerS , KarnerC , CatesCJ , EvansDJ . Inhaled corticosteroids versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 12. [DOI: 10.1002/14651858.CD007033.pub3] ">Spencer 2011</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007891-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007891-sec-0019"></div> <p>To compare the relative effects of inhaled combination therapy and tiotropium on markers of exacerbations, symptoms, quality of life, lung function, pneumonia and serious adverse events in patients with chronic obstructive pulmonary disease. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007891-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007891-sec-0020"></div> <section id="CD007891-sec-0021"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007891-sec-0022"> <h4 class="title">Types of studies</h4> <p>We included only randomised controlled trials with a parallel‐group design comparing the interventions. Studies were not excluded on the basis of blinding. We included studies of 12 weeks or more in duration. </p> </section> <section id="CD007891-sec-0023"> <h4 class="title">Types of participants</h4> <p>Populations with a diagnosis of chronic obstructive pulmonary disease. We only included studies where an external set of criteria had been used to screen participants for this condition (e.g. <a href="./references#CD007891-bbs2-0034" title="Global Initiative for Chronic Obstructive Lung Disease. http://www.goldcopd.com (accessed 18 February 2009). ">GOLD</a>, <a href="http://www.thoracic.org/sections/copd/index.html" target="_blank">ATS</a>, <a href="http://www.thoracic.org/sections/copd/index.html" target="_blank">BTS</a>, <a href="http://www.copdx.org.au/guidelines/a_copd_guidelines.asp" target="_blank">TSANZ</a>). </p> </section> <section id="CD007891-sec-0024"> <h4 class="title">Types of interventions</h4> <p>Inhaled combination corticosteroid and long‐acting beta<sub>2</sub>‐agonist (such as fluticasone/salmeterol, budesonide/formoterol, beclomethasone/formoterol) versus inhaled tiotropium bromide. </p> </section> <section id="CD007891-sec-0025"> <h4 class="title">Types of outcome measures</h4> <section id="CD007891-sec-0026"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD007891-list-0001"> <li> <p>Mortality (all‐cause)</p> </li> <li> <p>Hospital admission</p> </li> <li> <p>Exacerbations; all‐cause, requiring short courses of oral corticosteroids or antibiotics as defined by agreed criteria </p> </li> <li> <p>Pneumonia</p> </li> </ol> </p> </section> <section id="CD007891-sec-0027"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD007891-list-0002"> <li> <p>Quality of life (measured with a validated scale for COPD, e.g. St George's Respiratory Questionnaire, Chronic Respiratory Disease Questionnaire) </p> </li> <li> <p>Symptoms</p> </li> <li> <p>Forced expiratory volume in one second (FEV<sub>1</sub>) </p> </li> <li> <p>Non‐fatal serious adverse events</p> </li> <li> <p>Adverse events</p> </li> <li> <p>Withdrawals</p> </li> </ol> </p> </section> </section> </section> <section id="CD007891-sec-0028"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007891-sec-0029"> <h4 class="title">Electronic searches</h4> <p>We identified trials using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED and PsycINFO, and handsearching of respiratory journals and meeting abstracts (see <a href="./appendices#CD007891-sec-0081">Appendix 2</a> for further details). All records in the Specialised Register coded as 'COPD' were searched using the following terms: </p> <p>(tiotropium or spiriva) AND (((budesonide or fluticasone or beclomethasone or mometasone or steroid* or corticosteroid*) and (formoterol or salmeterol or indacaterol or (beta* and agonist*))) or (symbicort or viani or seretide or advair or foster or fostair or inuvair or combination*)) </p> <p>We conducted the latest search in November 2012.</p> </section> <section id="CD007891-sec-0030"> <h4 class="title">Searching other resources</h4> <p>We reviewed reference lists of all primary studies and review articles for additional references. We contacted authors of identified trials and manufacturers to ask if they knew of other published or unpublished studies. </p> </section> </section> <section id="CD007891-sec-0031"> <h3 class="title" id="CD007891-sec-0031">Data collection and analysis</h3> <section id="CD007891-sec-0032"> <h4 class="title">Selection of studies</h4> <p>Two review authors (EJW and CJC) screened the titles and abstracts of citations retrieved through literature searches and obtained full papers of references deemed to be potentially relevant. We assigned each reference to a study identifier and assessed them against the inclusion criteria of the review. </p> </section> <section id="CD007891-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>We extracted characteristics and data for studies that met the eligibility criteria of the review using a dedicated extraction sheet. The extraction of characteristics and data was performed in duplicate, and we identified and resolved discrepancies through discussion. </p> </section> <section id="CD007891-sec-0034"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias according to recommendations outlined in the <a href="./references#CD007891-bbs2-0032" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org (accessed 26 February 2009). ">Cochrane Handbook</a> for the following items: </p> <p> <ol id="CD007891-list-0003"> <li> <p>Allocation sequence generation</p> </li> <li> <p>Concealment of allocation</p> </li> <li> <p>Blinding of participants and investigators</p> </li> <li> <p>Handling of missing data</p> </li> </ol> </p> <p>We graded each potential source of bias as high, low or unclear risk of bias.</p> </section> <section id="CD007891-sec-0035"> <h4 class="title">Measures of treatment effect</h4> <p>We intended to combine dichotomous data variables (such as mortality, pneumonia and study withdrawal) as Peto odds ratios (OR) with 95% confidence intervals (CI) as this is more suitable than Mantel‐Haenszel for rare events. However, the events in <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> were not rare. We cross‐checked all the Peto odds ratios with the Mantel‐Haenszel odds ratios and found no difference, so we reported the Peto odds ratio as per protocol. We planned to combine continuous outcome data (such as symptoms, quality of life and FEV<sub>1</sub>) as fixed‐effect mean differences with 95% CI. In <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a>, exacerbations were reported as rate ratios (RR) and we entered these data into RevMan 5 using the GIV function (<a href="./references#CD007891-bbs2-0047" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). </p> </section> <section id="CD007891-sec-0036"> <h4 class="title">Unit of analysis issues</h4> <p>Data on exacerbations were provided by <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> trialists as the difference in exacerbation rates between patients on fluticasone/salmeterol and those on tiotropium, and were based on rate ratios using negative binomial model estimates and 95% confidence intervals. We entered the natural log of the rate ratio along with the standard error calculated from the confidence interval into RevMan 5 using the GIV function and cross‐checked the resulting confidence intervals with those provided by <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> for exacerbations. </p> <p>Data for quality of life and FEV<sub>1</sub> were calculated as a mean difference with 95% confidence intervals. We entered the mean difference and standard errors calculated from 95% CIs into RevMan 5 and analysed it using the GIV tool. </p> </section> <section id="CD007891-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors in order to verify key study characteristics and to obtain missing numerical data. </p> </section> <section id="CD007891-sec-0038"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess the amount of statistical variation between the study results with the I<sup>2</sup> statistic. </p> </section> <section id="CD007891-sec-0039"> <h4 class="title">Data synthesis</h4> <p>We planned to calculate numbers needed to treat from the pooled odds ratio and its confidence interval, and apply them to appropriate levels of baseline risk. </p> <p>We intended to present the findings of our four primary outcomes (mortality, hospital admission, exacerbations and pneumonia) in a 'Summary of findings' table generated using <a href="http://www.gradeworkinggroup.org/" target="_blank">GradePro</a> software. </p> </section> <section id="CD007891-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to subgroup studies according to:</p> <p> <ol id="CD007891-list-0004"> <li> <p>type and dose of combination therapy;</p> </li> <li> <p>severity of disease at baseline.</p> </li> </ol> </p> </section> <section id="CD007891-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We intended to assess the sensitivity of our primary outcomes to degree of bias. We planned to compare the Peto odds ratio results for dichotomous outcomes with Mantel‐Haenszel fixed‐effect and random‐effects models and with the pooled risk differences. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007891-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007891-sec-0042"></div> <section id="CD007891-sec-0043"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD007891-sec-0101" title="">Characteristics of included studies</a> and <a href="./references#CD007891-sec-0102" title="">Characteristics of excluded studies</a>. </p> <section id="CD007891-sec-0044"> <h4 class="title">Results of the search</h4> <p>The initial search was carried out in October 2009 and identified 81 references. Of these 13 were potentially relevant and were obtained in full text for further assessment. Eight of these full‐text documents were eligible and belonged to three included studies (<a href="./references#CD007891-bbs2-0006" title="DawberF , TandyD , HaussermannS , BetzR . Efficacy of fluticasone/salmeterol propionate 50/500mcg bd versus tiotropium on lung function and mucociliary clearance in COPD patients [Abstract]. Respirology2005;10(Suppl 3):A99. GSK(SCO4011) . A single centre, randomised, double‐blind, double dummy, parallel group 3‐week study to compare the effect of the fluticasone/salmeterol propionate combination 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhaler on mucociliary clearance rate in patients with Chronic Obstructive Pulmonary Disease (COPD). http://www.gsk‐clinicalstudyregister.com/files/pdf/23676.pdf (accessed 3 July 2009). ">Dawber 2005</a>, excluded in the 2012 update; <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a>; <a href="./references#CD007891-bbs2-0003" title="GSK(SCO40034) . A multicentre, randomised, double‐blind, double dummy, parallel group 12‐week exploratory study to compare the effect of the fluticasone/salmeterol propionate combination product (SERETIDE™) 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhalation device on efficacy and safety in patients with chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/23678.pdf (accessed 16 June 2009). ">SCO40034</a>). We asked five trialists if they knew of any other published and unpublished trials for the original version of this review; there were five responses but no relevant studies that had not already been located by the search were identified. Eight further references were returned by an updated search in March 2010, but none of these was eligible. A search in November 2012 identified 90 references of which one was eligible (<a href="./references#CD007891-bbs2-0001" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih [Chinese Journal of Tuberculosis &amp; Respiratory Diseases]2008;31(11):811‐4. [1001‐0939] ">Fang 2008</a>). </p> </section> <section id="CD007891-sec-0045"> <h4 class="title">Included studies</h4> <section id="CD007891-sec-0046"> <h5 class="title">Participants</h5> <p>A total of 1528 participants were recruited into the three eligible studies (<a href="./references#CD007891-bbs2-0001" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih [Chinese Journal of Tuberculosis &amp; Respiratory Diseases]2008;31(11):811‐4. [1001‐0939] ">Fang 2008</a>; <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a>; <a href="./references#CD007891-bbs2-0003" title="GSK(SCO40034) . A multicentre, randomised, double‐blind, double dummy, parallel group 12‐week exploratory study to compare the effect of the fluticasone/salmeterol propionate combination product (SERETIDE™) 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhalation device on efficacy and safety in patients with chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/23678.pdf (accessed 16 June 2009). ">SCO40034</a>). <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> was by far the largest included trial, with 1323 participants, whilst <a href="./references#CD007891-bbs2-0003" title="GSK(SCO40034) . A multicentre, randomised, double‐blind, double dummy, parallel group 12‐week exploratory study to compare the effect of the fluticasone/salmeterol propionate combination product (SERETIDE™) 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhalation device on efficacy and safety in patients with chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/23678.pdf (accessed 16 June 2009). ">SCO40034</a> had 125 participants and <a href="./references#CD007891-bbs2-0001" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih [Chinese Journal of Tuberculosis &amp; Respiratory Diseases]2008;31(11):811‐4. [1001‐0939] ">Fang 2008</a> had 80 patients in the relevant treatment arms. <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> was a two‐year trial, <a href="./references#CD007891-bbs2-0001" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih [Chinese Journal of Tuberculosis &amp; Respiratory Diseases]2008;31(11):811‐4. [1001‐0939] ">Fang 2008</a> was a year long and <a href="./references#CD007891-bbs2-0003" title="GSK(SCO40034) . A multicentre, randomised, double‐blind, double dummy, parallel group 12‐week exploratory study to compare the effect of the fluticasone/salmeterol propionate combination product (SERETIDE™) 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhalation device on efficacy and safety in patients with chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/23678.pdf (accessed 16 June 2009). ">SCO40034</a> was 12 weeks in duration. Owing to the disparity in the trial lengths and because the primary focus of our review was on long‐term outcomes, we did not pool the results of the trials. We could not find a contact email address for the author of <a href="./references#CD007891-bbs2-0001" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih [Chinese Journal of Tuberculosis &amp; Respiratory Diseases]2008;31(11):811‐4. [1001‐0939] ">Fang 2008</a>, therefore we were unable to contact them to ask for clarification of the data. This was disappointing because if the trialists had been able to provide the raw data we could have used it. Due to our concerns about inconsistency and possible errors in the data we were unable to incorporate the data into meta‐analysis and therefore we added the data narratively where possible. This review therefore focusses primarily on the results of <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a>. </p> <p>Patients in <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> were classified as having GOLD stage III (FEV<sub>1</sub> ≥ 30% to &lt; 50% predicted) or GOLD stage IV (FEV<sub>1</sub> &lt; 30% predicted). There were N = 540 patients with stage III COPD on fluticasone/salmeterol with a mean FEV<sub>1</sub> of 1.09 L and N = 537 patients with a mean FEV<sub>1</sub> of 1.11 L on tiotropium. There were N = 100 patients with stage IV COPD on fluticasone/salmeterol with a mean FEV<sub>1</sub> of 0.73 L and N = 101 patient with a mean FEV<sub>1</sub> of 0.71 L on tiotropium. In <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a>, 48% of participants in the fluticasone/salmeterol arm and 51% in the tiotropium arm stopped taking inhaled corticosteroids at baseline. All participants had a smoking history of greater than 10 pack‐years. </p> </section> <section id="CD007891-sec-0047"> <h5 class="title">Interventions</h5> <p>Patients recruited to <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> received either fluticasone/salmeterol (500/50 µg twice a day) as a dry powder via a DISKUS or Accuhaler inhaler or tiotropium (18 μg once a day) delivered via a dry‐powder Handihaler. </p> <p>Participants in <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> were allowed to take short‐acting beta<sub>2</sub>‐agonists and short courses of oral corticosteroids alongside their study medications. Prior to randomisation, participants in <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> were given oral prednisolone (30 mg) once a day and inhaled fluticasone/salmeterol (500/50 μg) twice a day during a two‐week run‐in period. </p> </section> <section id="CD007891-sec-0048"> <h5 class="title">Outcomes</h5> <p>The primary outcomes varied between the studies and were different from our primary outcomes. The primary outcome for <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> was the rate of health care utilisation for COPD exacerbations, which we incorporated into our review. <a href="./references#CD007891-bbs2-0003" title="GSK(SCO40034) . A multicentre, randomised, double‐blind, double dummy, parallel group 12‐week exploratory study to compare the effect of the fluticasone/salmeterol propionate combination product (SERETIDE™) 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhalation device on efficacy and safety in patients with chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/23678.pdf (accessed 16 June 2009). ">SCO40034</a> was an exploratory study to compare the clinical efficacy of fluticasone/salmeterol against tiotropium and therefore did not define a primary outcome. </p> </section> </section> <section id="CD007891-sec-0049"> <h4 class="title">Excluded studies</h4> <p>Five studies failed to meet the eligibility criteria for the review and reasons for exclusion are reported in the <a href="./references#CD007891-sec-0102" title="">Characteristics of excluded studies</a> table. Three trials (<a href="./references#CD007891-bbs2-0007" title="GolabiP , TopalogluN , KarakurtS , CelikelT . Effects of tiotropium and fluticasone/salmeterol combination on lung hyperinflation dyspnea and exercise tolerance in COPD [Abstract]. European Respiratory Journal2006;28(Suppl 50):33s [E304]. ">Golabi 2006</a>; <a href="./references#CD007891-bbs2-0010" title="HaraK , KurashimaK , TokunagaD , UenoM , AoyagiK , IsobeZ , et al. Single blind comparison of tiotropium and salmeterol plus fluticasone propionate of treatment in patients with chronic obstructive pulmonary disease (COPD) [Abstract]. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA2007:Poster #A1. ">Hara 2007</a>; <a href="./references#CD007891-bbs2-0021" title="SinghD , BrooksJ , HaganG , CahnA , O'ConnorBJ . Superiority of &quot;triple&quot; therapy with fluticasone/salmeterol propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax2008;63(7):592‐8. ">Singh 2008</a>) were excluded because they were cross‐over trials, which are not suitable for assessing long‐term outcomes. </p> <p>One trial (<a href="./references#CD007891-bbs2-0004" title="BatemanED , vanDykM , SagriotisA . Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study. Pulmonary Pharmacology and Therapeutics2008;21(1):20‐5. ">Bateman 2008</a>) was excluded because the intervention compared fluticasone (250 μg) and salmeterol (50 μg) administered via separate metered dose inhalers to tiotropium (18 μg). We felt that this could lead to discrepancies in the analysis if participants stopped taking one inhaler and continued taking the other. This randomised, double‐blind, triple‐dummy pilot study administered fluticasone and salmeterol to 51 participants and tiotropium to 56 participants. The participants had moderate or severe COPD and a smoking history of greater than 10 pack‐years although the baseline characteristics were not comparable across both arms. The primary outcome was FEV<sub>1</sub> and there was no significant difference in the lung function or occurrence of adverse effects between the two intervention arms after 43 days and there was a single dropout in the fluticasone/salmeterol arm. We excluded a trial that was included in the original version of this review (<a href="./references#CD007891-bbs2-0006" title="DawberF , TandyD , HaussermannS , BetzR . Efficacy of fluticasone/salmeterol propionate 50/500mcg bd versus tiotropium on lung function and mucociliary clearance in COPD patients [Abstract]. Respirology2005;10(Suppl 3):A99. GSK(SCO4011) . A single centre, randomised, double‐blind, double dummy, parallel group 3‐week study to compare the effect of the fluticasone/salmeterol propionate combination 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhaler on mucociliary clearance rate in patients with Chronic Obstructive Pulmonary Disease (COPD). http://www.gsk‐clinicalstudyregister.com/files/pdf/23676.pdf (accessed 3 July 2009). ">Dawber 2005</a>) as we introduced a minimum trial duration of 12 weeks. </p> </section> </section> <section id="CD007891-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>An assessment of the risk of bias is presented in the <a href="./references#CD007891-sec-0101" title="">Characteristics of included studies</a> table and summarised in a 'Risk of bias' table (<a href="#CD007891-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD007891-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007891-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD007891-sec-0051"> <h4 class="title">Allocation</h4> <p><a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> reported adequate sequence generation and allocation concealment. <a href="./references#CD007891-bbs2-0003" title="GSK(SCO40034) . A multicentre, randomised, double‐blind, double dummy, parallel group 12‐week exploratory study to compare the effect of the fluticasone/salmeterol propionate combination product (SERETIDE™) 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhalation device on efficacy and safety in patients with chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/23678.pdf (accessed 16 June 2009). ">SCO40034</a> did not report full details in the study report, but GSK supplied unpublished information describing adequate computerised randomisation and allocation on request. <a href="./references#CD007891-bbs2-0001" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih [Chinese Journal of Tuberculosis &amp; Respiratory Diseases]2008;31(11):811‐4. [1001‐0939] ">Fang 2008</a> stated that they used random number tables, but no information was provided on allocation concealment. </p> </section> <section id="CD007891-sec-0052"> <h4 class="title">Blinding</h4> <p><a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> and <a href="./references#CD007891-bbs2-0003" title="GSK(SCO40034) . A multicentre, randomised, double‐blind, double dummy, parallel group 12‐week exploratory study to compare the effect of the fluticasone/salmeterol propionate combination product (SERETIDE™) 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhalation device on efficacy and safety in patients with chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/23678.pdf (accessed 16 June 2009). ">SCO40034</a> were blinded by employing a double‐dummy design; the two drugs were administered via different types of inhaler, each participant was given two inhalers to use each day, one containing the intervention medication and a second containing placebo. Neither the patient nor the investigator knew what medication a particular participant was randomised to. Blinding was not stated or described in <a href="./references#CD007891-bbs2-0001" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih [Chinese Journal of Tuberculosis &amp; Respiratory Diseases]2008;31(11):811‐4. [1001‐0939] ">Fang 2008</a>, indeed the non‐intervention arm did not appear to have a placebo and we took this as confirmation that the relevant treatment arms were not blinded. </p> </section> <section id="CD007891-sec-0053"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> suffered from high withdrawal rates and data were not collected for patients who withdrew. For a discussion of the methodological issues affecting COPD trials see <a href="#CD007891-sec-0067">Discussion</a>. </p> </section> <section id="CD007891-sec-0054"> <h4 class="title">Selective reporting</h4> <p>Two trials adequately reported outcome data for the primary and secondary outcomes that they had pre‐specified in the study record (<a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a>; <a href="./references#CD007891-bbs2-0003" title="GSK(SCO40034) . A multicentre, randomised, double‐blind, double dummy, parallel group 12‐week exploratory study to compare the effect of the fluticasone/salmeterol propionate combination product (SERETIDE™) 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhalation device on efficacy and safety in patients with chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/23678.pdf (accessed 16 June 2009). ">SCO40034</a>). </p> </section> </section> <section id="CD007891-sec-0055"> <h3 class="title" id="CD007891-sec-0055">Effects of interventions</h3> <section id="CD007891-sec-0056"> <h4 class="title">Primary outcome: Mortality (all‐cause)</h4> <p>In <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a>, there were more deaths on tiotropium (38/665 people) than on fluticasone/salmeterol (21/658) (Peto odds ratio (OR) 0.55; 95% confidence interval (CI) 0.33 to 0.93). Although this was a statistically significant difference, the number of withdrawals from each of the arms was 11 times larger than the number of deaths for participants on fluticasone/salmeterol and seven times larger for participants on tiotropium. This uncertainty about the results is not reflected in the confidence interval for the odds ratio. </p> </section> <section id="CD007891-sec-0057"> <h4 class="title">Primary outcome: Hospital admission</h4> <p>There were more all‐cause hospital admissions in patients on fluticasone/salmeterol (215/658) than those on tiotropium (179/665) in <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> (Peto OR 1.32; 95% CI 1.04 to 1.67). The primary outcome of <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> was hospital admissions due to exacerbations. More patients on salmeterol/fluticasone were hospitalised due to exacerbations (105/658) compared to tiotropium (86/665) (Peto OR 1.28; 95% CI 0.94 to 1.74), but this was not statistically significant. </p> </section> <section id="CD007891-sec-0058"> <h4 class="title">Primary outcome: Exacerbations</h4> <p>Data for all‐cause exacerbations were reported as both count data and as a rate (i.e. the mean number of exacerbations per year) in <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a>. The differences between these methods of analysis are discussed in the <a href="#CD007891-sec-0069">Summary of main results</a>. </p> <p>Firstly, there was no significant difference in the number of people experiencing one or more exacerbations (408/658 in the fluticasone/salmeterol arm versus 393/665 in the tiotropium arm; <a href="./references#CD007891-fig-0004" title="">Analysis 1.3</a>). </p> <p>The number of exacerbations was also reported as the mean number of events per year. There was no significant difference in exacerbations of any type in patients on fluticasone/salmeterol compared to tiotropium (rate ratio (RR) 0.97; 95% CI 0.84 to 1.12; <a href="./references#CD007891-fig-0005" title="">Analysis 1.4</a>). Overall 62% of the fluticasone/salmeterol group and 59% of the tiotropium group had one or more exacerbation requiring therapeutic intervention and the trialists estimated this to equate to 1.28 and 1.32 exacerbation per year for patients on fluticasone/salmeterol and tiotropium respectively. Exacerbations requiring treatment with oral corticosteroids were more frequent in patients on tiotropium (RR 0.81; 95% CI 0.67 to 0.99) and conversely exacerbations requiring treatment with antibiotics were more frequent in patients treated with fluticasone/salmeterol (RR 1.19; 95% CI 1.02 to 1.38). </p> </section> <section id="CD007891-sec-0059"> <h4 class="title">Primary outcome: Pneumonia</h4> <p>There were more cases of pneumonia in patients on fluticasone/salmeterol (50/658) than in those on tiotropium (24/665) (Peto OR 2.13; 95% CI 1.33 to 3.40). There were several figures reported for pneumonia in the <a href="http://archie.cochrane.org/sections/documents/view?version=68242241490932923665100127150635%26format=REVMAN#STD-INSPIRE" target="_blank">INSPIRE</a> trial (see <a href="#CD007891-tbl-0001">Table 1</a>) all of which indicated that there were more cases of pneumonia in participants on fluticasone/salmeterol compared to those on tiotropium. While this is statistically significant, there is considerable uncertainty over the clinical interpretation of this result owing to the large dropout rates. Moreover, if this is a true finding, the higher pneumonia rate in the combination group was not associated with a significant increase in exacerbations, hospitalisations due to exacerbations or deaths. </p> <div class="table" id="CD007891-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Differences in the reported cases of pneumonia in the INSPIRE trial</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonias recorded in patients treated with fluticasone/salmeterol</b> </p> <p><b>Number (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonias recorded in patients treated with tiotropium</b> </p> <p><b>Number (%)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Most frequent adverse effects on ITT population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (3)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (3)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatal serious adverse events*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (&lt; 1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events including pneumonia, lobar pneumonia and bronchopneumonia**</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (4)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Reported in SCO40035.</p> <p>**Reported in Wedzicha 2008.</p> <p>ITT: intention‐to‐treat</p> </div> </div> </section> <section id="CD007891-sec-0060"> <h4 class="title">Secondary outcome: Quality of life</h4> <p>Patients on fluticasone/salmeterol reported better quality of life than those on tiotropium at two years from baseline (mean difference (MD) ‐2.07; 95% CI ‐4.02 to ‐0.12). In real terms, this meant that patients on salmeterol/fluticasone reported a mean improvement in quality of life of 1.7 units on the St. Georges Respiratory Questionnaire (<a href="./references#CD007891-bbs2-0048" title="JonesP . St George Respiratory Questionnaire. http://www.healthstatus.sgul.ac.uk/downloads/respiratory_questionairre.htm (accessed 6 October 2009). ">SGRQ</a>) whilst those on tiotropium reported a mean worsening in their quality of life of 0.4 units. The minimum clinically important difference in quality of life measured on the SGRQ is four units. <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> reported that 35% of patients on fluticasone/salmeterol and 27% patients on tiotropium (OR 1.29; 95% CI 1.04 to 1.60) experienced an improvement in quality of life of ≥ four units. Data for the number of patients who had a deterioration in quality of life of ≥ four units was not reported (<a href="./references#CD007891-bbs2-0036" title="JonesPW . Triple therapy for chronic obstructive pulmonary disease: trials catching up with clinical practice?. American Journal of Respiratory and Critical Care Medicine2009;180(8):689‐90. ">Jones 2009</a>). </p> </section> <section id="CD007891-sec-0061"> <h4 class="title">Secondary outcome: Symptoms</h4> <p>Outcome not reported.</p> </section> <section id="CD007891-sec-0062"> <h4 class="title">Secondary outcome: Forced expiratory volume in one second (FEV<sub>1</sub>) </h4> <p>FEV<sub>1</sub> data were available at a number of time points in <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> and therefore we entered data at both eight weeks and two years. At eight weeks, FEV<sub>1</sub> had increased by 0.04 L (± 0.010) from baseline in patients on fluticasone/salmeterol, whilst those on tiotropium had an increase of 0.06 L (± 0.010). There was no statistically significant between‐group difference (MD ‐0.02; 95% CI ‐0.05 to 0.01). At two years, the FEV<sub>1</sub> of patients on fluticasone/salmeterol had decreased by ‐0.01 L (± 0.012) compared to baseline whilst those on tiotropium showed an improvement compared to baseline of FEV<sub>1</sub> 0.01 L (± 0.013), again not a statistically significant between‐group difference (MD ‐0.02; 95% CI ‐0.05 to 0.01). </p> </section> <section id="CD007891-sec-0063"> <h4 class="title">Secondary outcome: Serious adverse events (non‐fatal)</h4> <p>There were more serious adverse events in patients on fluticasone/salmeterol (194/658) than in patients on tiotropium (141/665) (Peto OR 1.55; 95% CI 1.21 to 1.98) in <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a>. </p> </section> <section id="CD007891-sec-0064"> <h4 class="title">Secondary outcome: Adverse events</h4> <p>In <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> there were fewer adverse events among patients on fluticasone/salmeterol (435/658) than tiotropium (414/665) (Peto OR 1.18; 95% CI 0.94 to 1.48). </p> </section> <section id="CD007891-sec-0065"> <h4 class="title">Secondary outcome: Withdrawal</h4> <p>There were large numbers of withdrawals from <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> and the withdrawal rate was higher in the tiotropium group than in the fluticasone/salmeterol group. There were fewer withdrawals for any reason for patients on fluticasone/salmeterol (232/658, 35%) compared with tiotropium (279/665, 42%) (Peto OR 0.75; 95% CI 0.60 to 0.94). The difference between the number withdrawing due to adverse events (Peto OR 1.03; 95% CI 0.72 to 1.47) and lack of efficacy (Peto OR 0.84; 95% CI 0.52 to 1.37) was not statistically significant. The <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> trialists reported reasons for withdrawal (<a href="#CD007891-tbl-0002">Table 2</a>) and this demonstrated that the greatest difference was higher rates of withdrawal due to COPD exacerbations in patients on tiotropium than in those on fluticasone/salmeterol. </p> <div class="table" id="CD007891-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Reasons for withdrawals from INSPIRE</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reason for withdrawal</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fluticasone/salmeterol</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tiotropium</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrew consent</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lost to follow‐up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Protocol violation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failed entry criteria</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>COPD exacerbation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lack of efficacy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232 (35.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279 (42.0%)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>COPD: chronic obstructive pulmonary disease</p> </div> </div> <p>There were no data reported for symptoms.</p> </section> <section id="CD007891-sec-0066"> <h4 class="title">Summary of results for Fang 2008 and SCO40034</h4> <p>There were no deaths in <a href="./references#CD007891-bbs2-0003" title="GSK(SCO40034) . A multicentre, randomised, double‐blind, double dummy, parallel group 12‐week exploratory study to compare the effect of the fluticasone/salmeterol propionate combination product (SERETIDE™) 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhalation device on efficacy and safety in patients with chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/23678.pdf (accessed 16 June 2009). ">SCO40034</a>. There was no significant difference in hospital admissions, cases of pneumonia, FEV<sub>1</sub>, serious adverse events or adverse events in <a href="./references#CD007891-bbs2-0003" title="GSK(SCO40034) . A multicentre, randomised, double‐blind, double dummy, parallel group 12‐week exploratory study to compare the effect of the fluticasone/salmeterol propionate combination product (SERETIDE™) 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhalation device on efficacy and safety in patients with chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/23678.pdf (accessed 16 June 2009). ">SCO40034</a>. There were more withdrawals in patients on tiotropium compared to fluticasone/salmeterol in patients in the <a href="./references#CD007891-bbs2-0003" title="GSK(SCO40034) . A multicentre, randomised, double‐blind, double dummy, parallel group 12‐week exploratory study to compare the effect of the fluticasone/salmeterol propionate combination product (SERETIDE™) 50/500mcg bd via the DISKUS™/ACCUHALER™ inhaler with tiotropium bromide 18 mcg od via the Handihaler inhalation device on efficacy and safety in patients with chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/23678.pdf (accessed 16 June 2009). ">SCO40034</a> trial. </p> <p><a href="./references#CD007891-bbs2-0001" title="FangLZ , LiangX , ZhangJQ , LiuL , FuWP , ZhaoZH , et al. Combination of inhaled salmeterol/fluticasone and tiotropium in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Chung‐Hua Chieh Ho Ho Hu Hsi Tsa Chih [Chinese Journal of Tuberculosis &amp; Respiratory Diseases]2008;31(11):811‐4. [1001‐0939] ">Fang 2008</a> reported no significant difference in absolute number of adverse events between treatment groups. Pre‐ and post‐bronchodilator FEV<sub>1</sub> were reported at the end of study, but we were not confident that the number reported represented the standard error. SGRQ score was reported, but the numbers appeared to differ between what was in the text of the trial report and those in a table; we were therefore unable to use the data. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007891-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007891-sec-0067"></div> <section id="CD007891-sec-0068"> <h3 class="title" id="CD007891-sec-0068">Methodological issues in chronic obstructive pulmonary disease (COPD) trials</h3> <p>Withdrawal rates in COPD trials are commonly high, especially in studies longer than six months in duration. There is no consensus on how to handle participants for whom data are not available (<a href="./references#CD007891-bbs2-0032" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org (accessed 26 February 2009). ">Cochrane Handbook</a>). There are two available options: intention‐to‐treat analysis or available case analysis. </p> <p>The principles of intention‐to‐treat analyses are that participants are analysed according to the intervention group to which they were initially randomised regardless of the treatment received. Outcome data are recorded for all participants and all randomised participants are included in the analysis. Performing analyses on a true intention‐to‐treat basis when outcome data for all participants are missing is not possible. To perform an intention‐to‐treat analysis regardless of the missing data does not take into account participants who withdraw and gives an overly precise estimate of the treatment effect. When withdrawals are related to the treatment (i.e. not at random), the participants who withdraw are likely to have poorer outcomes than those who remain in the trial and provide data (<a href="./references#CD007891-bbs2-0052" title="SuissaS , ErnstP , VandemheenK L , AaronSD . Methodological issues in therapeutic trials of COPD. European Respiratory Journal2008;31(5):927‐33. ">Suissa 2008</a>). This can lead to a 'healthy survivor' effect. </p> <p>One way to deal with missing outcome data due to withdrawals is imputation and there are three ways of estimating missing values. One approach is to assume that the rate of events in the participants who withdraw occurs at the same rate as it does in those who remained in the study and provide data. This increases the precision of the estimate of the confidence intervals, but if the assumed rate of events is incorrect, the effect estimate for the study will be biased. A second option is to simulate best‐case worst‐case scenarios, where it is assumed that all the participants who withdrew from one intervention arm experienced the event and then repeat the analysis with the other intervention arm, comparing the results as a sensitivity analysis. This is problematic when the number of dropouts is significantly greater than the numbers of patients experiencing the event in the study. The third way is to assume that the rates of events in the withdrawals is similar to those observed in other similar trials. </p> <p>However, full follow‐up of patients that withdraw can introduce a different bias. Patients that withdraw are likely to begin treatment with another medication, but their outcomes are still attributed to the treatment group to which they were randomised. This is particularly problematic in head‐to‐head studies because patients often go onto the other study medication, which could potentially provide an inaccurate estimate of the true difference between the treatments. </p> <p>Available case analysis, where treatment effect is based on the number of participants who provided data, does not take into account the outcomes of those who withdrew. </p> <p>COPD patients who withdraw early tend to be sicker at recruitment and deteriorate faster than those who remain in the study. Additionally, because COPD is a chronic condition, many patients are already taking medication when they start a clinical trial and withdrawal symptoms can occur (<a href="./references#CD007891-bbs2-0052" title="SuissaS , ErnstP , VandemheenK L , AaronSD . Methodological issues in therapeutic trials of COPD. European Respiratory Journal2008;31(5):927‐33. ">Suissa 2008</a>). In effect a trial can be looking at the effect of withdrawing an existing treatment as well as introducing a new one. </p> <p>Participants in COPD trials are usually already taking medication for their condition before entry. Run‐in periods, where participants take a standard treatment for a few weeks prior to randomisation were designed to account for the improvement in health status that comes at the start of a trial due to increased medical attention (<a href="./references#CD007891-bbs2-0030" title="CalverleyPM , BoonsawatW , CsekeZ , ZhongN , PetersonS , OlssonH . Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. European Respiratory Journal2003;22(6):912‐9. ">Calverley 2003</a>). However, these run‐in periods limit the overall applicability of the results if the outcomes were affected by the run‐in drugs, but attributed to the study medication (<a href="./references#CD007891-bbs2-0053" title="SuissaS . Methodologic shortcomings of the INSPIRE randomized trial. American Journal of Respiratory and Critical Care Medicine2008;178(10):1090‐1. ">Suissa 2008a</a>). </p> </section> <section id="CD007891-sec-0069"> <h3 class="title" id="CD007891-sec-0069">Summary of main results</h3> <p>The number of withdrawals from both arms of the <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> trial was large and outcome data were not collected for patients who withdrew. It is feasible to record mortality data (vital status) for participants who withdrew, but not reasonably possible to obtain data for other outcomes. Because outcome data for those who withdrew were not available, the confidence intervals for the outcomes do not reflect this additional uncertainty. We cannot be sure that the mortality rate for patients who withdrew on either drug was higher, lower or the same as those who completed the study. It would be, in our opinion, inappropriate to apply simple imputation of data in this instance. </p> <p>When patients withdraw from a study for reasons relating to outcomes, the perceived benefit (or lack thereof) of a study drug can have great influence over their decision to remain in the trial (<a href="./references#CD007891-bbs2-0042" title="KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30:898‐906. ">Kesten 2007</a>). <a href="./references#CD007891-bbs2-0042" title="KestenS , PlautzM , PiquetteCA , HabibMP , NiewoehnerDE . Premature discontinuation of patients: a potential bias in COPD clinical trials. European Respiratory Journal2007;30:898‐906. ">Kesten 2007</a> reported higher incidence rates of death following premature discontinuation of study medication. <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> trialists cited the differential withdrawal rate as an indirect marker of treatment efficacy. There was no significant difference in the withdrawals due to lack of efficacy or adverse events in <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> although more people on tiotropium withdrew compared to those on fluticasone/salmeterol overall. The proportion of missing outcome data compared to the observed outcome data is enough to induce a clinically relevant bias in the intervention effect. </p> <p>We presented exacerbations using two different units of analysis in this review. There are several ways to analyse exacerbation rates and each is associated with advantages or disadvantages (<a href="./references#CD007891-bbs2-0041" title="KeeneON , CalverleyPMA , JonesPW , VestboJ , AndersonJA . Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. European Respiratory Journal2008;32:17–24. ">Keene 2008</a>). Looking at the number of patients experiencing one or more exacerbations does not give any information about exacerbation frequency in the same patient and does not take into account duration of study (<a href="./references#CD007891-bbs2-0037" title="KarnerC , CatesCJ . Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD008532.pub2] ">Karner 2011</a>; <a href="./references#CD007891-bbs2-0041" title="KeeneON , CalverleyPMA , JonesPW , VestboJ , AndersonJA . Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited. European Respiratory Journal2008;32:17–24. ">Keene 2008</a>). You therefore get different information from the number of people experiencing one or more exacerbations and the mean number of exacerbations per year. While neither of the methods of reporting all‐cause exacerbations resulted in a statistically significant difference, it is interesting to note that the direction of the treatment effect is different. Reported as number of people experiencing one or more exacerbations, there are fewer exacerbations in people on tiotropium. However looking at the relative rate, there are fewer exacerbations <i>per year</i> in patients on fluticasone/salmeterol. This may represent the play of chance, but we cannot rule out the possibility that the two treatments have different impacts on patients with occasional or frequent exacerbations. </p> </section> <section id="CD007891-sec-0070"> <h3 class="title" id="CD007891-sec-0070">Quality of the evidence</h3> <p>Two trials had adequate sequence generation, allocation concealment and blinding. One was unblinded and did not report how allocation concealment was attempted and we were not able to contact the trialist to find out. Additionally, data were provided for the outcomes outlined in the protocols of the trials. The principal concern with the largest study addressing the review question (<a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a>) relates to the handling of data from participants who withdrew. </p> </section> <section id="CD007891-sec-0071"> <h3 class="title" id="CD007891-sec-0071">Potential biases in the review process</h3> <p>We minimised bias in our search process thorough using comprehensive search terms and asking authors to identify other published an non‐published studies. Studies were determined as included or excluded, data were extracted and risk of bias attributed in duplicate to minimise error. </p> </section> <section id="CD007891-sec-0072"> <h3 class="title" id="CD007891-sec-0072">Agreements and disagreements with other studies or reviews</h3> <p>Previous systematic reviews evaluating combined inhalers compared to placebo (<a href="./references#CD007891-bbs2-0044" title="NanniniLJ , CatesCJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003794.pub3] ">Nannini 2007a</a>) and combined inhalers compared to long‐acting beta<sub>2</sub>‐agonists (<a href="./references#CD007891-bbs2-0046" title="NanniniLJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2012, Issue 9. [DOI: 10.1002/14651858.CD006829.pub2] ">Nannini 2012</a>) have shown an elevated risk of pneumonia with combination therapy (see <a href="#CD007891-tbl-0003">Table 3</a>). There were relatively more cases of pneumonia reported in these systematic reviews (which included <a href="./references#CD007891-bbs2-0054" title="CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. [1533‐4406: (Electronic)] ">TORCH</a>) and <a href="./references#CD007891-bbs2-0054" title="CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. [1533‐4406: (Electronic)] ">TORCH</a> than were recorded in <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a>. </p> <div class="table" id="CD007891-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Proportion of participants developing pneumonia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia on FPS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia on comparison treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial duration, weeks</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia on FPS per 52 weeks</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia on comparison per 52 weeks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naninni 2007a<sup>†</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325/2673 (12%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194/2556 (8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TORCH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303/1546 (20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164/1544 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naninni 2012<sup>†</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>447/5922</p> <p>(7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280/5154 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TORCH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303/1546 (20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205/1542 (13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>INSPIRE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50/658 (8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/665 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8%</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>†</sup>Includes data from TORCH. </p> <p>*Weighted mean trial duration.</p> <p>FPS: fluticasone/salmeterol <br/> LABA: long‐acting beta<sub>2</sub>‐agonist </p> </div> </div> <p>There were relatively fewer deaths in <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> compared to <a href="./references#CD007891-bbs2-0054" title="CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. [1533‐4406: (Electronic)] ">TORCH</a> that included complete follow‐up of vital status for participants who withdrew; 1.6% per year in <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> compared to 4.2% per year in <a href="./references#CD007891-bbs2-0054" title="CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. [1533‐4406: (Electronic)] ">TORCH</a>. There may have been at least as many deaths in patients who withdrew from <a href="./references#CD007891-bbs2-0002" title="CalverleyP , StockleyR , SeemungalT , HaganG , WedzichaJ . Adverse events and mortality in the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):125s [P847]. CalverleyPM , StockleyRA , SeemungalTA , HaganG , WillitsLR , RileyJH , et al. Reported pneumonia in patients with COPD: Findings from the INSPIRE study. Chest2011;139(3):505‐12. GSK(SCO40036) . Multicentre, randomised, double‐blind, double dummy, parallel group, 104‐week study to compare the effect of the salmeterol/fluticasone propionate combination product (SERETIDE*) 50/500mcg delivered twice daily via the DISKUS*/ACCUHALER* inhaler with tiotropium bromide 18 mcg delivered once daily via the Handihaler inhalation device on the rate of health care utilisation exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). www.gsk‐clinicalstudyregister.com/files/pdf/21085.pdf (accessed 16 June 2009). SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations) [Abstract]. European Respiratory Journal2007;30(Suppl 51):688s [E4055]. SeemungalT , StockleyR , CalverleyP , HaganG , WedzichaJA . Investigating new standards for prophylaxis in reduction of exacerbations ‐ The INSPIRE study methodology. COPD: Journal of Chronic Obstructive Pulmonary Disease2007;4(3):177‐83. StockleyR , CalverleyP , SeemungalT , HaganG , WedzichaJ . Effect of fluticasone/salmeterol propionate versus tiotropium bromide on withdrawal rate, health status, lung function and mortality INSPIRE (investigating new standards for prophylaxis in reduction of exacerbations study) [Abstract]. European Respiratory Journal2007;30(Suppl 51):34s [388]. WedzichaJ , StockleyR , SeemungalT , HaganG , CalverleyP . The INSPIRE study: effect of fluticasone/salmeterol propionate versus tiotropium bromide on COPD exacerbations [Abstract]. Respirology2007;12(Suppl 4):A112. WedzichaJA , CalverleyPM , SeemungalTA , HaganG , AnsariZ , StockleyRA , et al. The prevention of chronic obstructive pulmonary disease exacerbations by fluticasone/salmeterol propionate or tiotropium bromide. American Journal of Respiratory &amp; Critical Care Medicine2008;177(1):19‐26. ">INSPIRE</a> as in those who completed the trial. </p> <section id="CD007891-sec-0073"> <h4 class="title">Indirect comparison</h4> <p>There are two Cochrane reviews that may serve as a useful indirect comparison of treatment efficacy: combination inhaled steroids and long‐acting beta‐agonists versus placebo (<a href="./references#CD007891-bbs2-0044" title="NanniniLJ , CatesCJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003794.pub3] ">Nannini 2007a</a>) and tiotropium versus placebo (<a href="./references#CD007891-bbs2-0029" title="BarrRG , BourbeauJ , CamargoCA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a>). We include the following descriptions for comparison only and have not calculated an estimate of relative benefits and harms from these meta‐analyses. </p> <p><a href="./references#CD007891-bbs2-0044" title="NanniniLJ , CatesCJ , LassersonTJ , PooleP . Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD003794.pub3] ">Nannini 2007a</a> reported outcomes for a total of 6427 participants in 11 studies. Two studies compared budesonide/formoterol, while the remaining studies compared fluticasone/salmeterol, albeit at different doses. The meta‐analysis was dominated by the largest trial (<a href="./references#CD007891-bbs2-0054" title="CalverleyPM , AndersonJA , CelliB , FergusonGT , JenkinsC , JonesPW , et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. New England Journal of Medicine2007;356(8):775‐89. [1533‐4406: (Electronic)] ">TORCH</a>) which had complete follow‐up for vital status of all participants. All‐cause mortality was reduced in patients on combined inhalers compared to placebo (OR 0.79; 95% CI 0.65 to 0.96). Exacerbations were less frequent in participants on combined inhalers (rate ratio 0.74; 95% CI 0.7 to 0.8) and an increase in the risk of pneumonia was noted in the groups that received inhaled steroids either alone or in combination. </p> <p><a href="./references#CD007891-bbs2-0029" title="BarrRG , BourbeauJ , CamargoCA . Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002876.pub2] ">Barr 2005</a> reported outcomes for a total of 6584 participants across nine studies, comparing tiotropium to placebo, ipratropium or long‐acting beta<sub>2</sub>‐agonist. All‐cause mortality was reduced in participants on tiotropium compared to placebo (OR 0.73; 95% CI 0.35 to 1.49) and COPD exacerbations were also reduced (OR 0.75; 95% CI 0.66 to 0.85). The only adverse event data available to pool was for dry mouth which was more frequently experienced by patients randomised to tiotropium than placebo. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007891-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/urn:x-wiley:14651858:media:CD007891:CD007891-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_t/tCD007891-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD007891-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/full#CD007891-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007891-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/urn:x-wiley:14651858:media:CD007891:CD007891-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_t/tCD007891-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 1 Mortality (all‐cause)." data-id="CD007891-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 1 Mortality (all‐cause). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/references#CD007891-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007891-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/urn:x-wiley:14651858:media:CD007891:CD007891-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_t/tCD007891-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 2 Hospital admission." data-id="CD007891-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 2 Hospital admission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/references#CD007891-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007891-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/urn:x-wiley:14651858:media:CD007891:CD007891-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_t/tCD007891-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 3 Exacerbations (all‐cause): number of patients experiencing one or more exacerbations over two years." data-id="CD007891-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 3 Exacerbations (all‐cause): number of patients experiencing one or more exacerbations over two years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/references#CD007891-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007891-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/urn:x-wiley:14651858:media:CD007891:CD007891-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_t/tCD007891-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 4 Exacerbations (mean number of exacerbations per patient per year)." data-id="CD007891-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 4 Exacerbations (mean number of exacerbations per patient per year). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/references#CD007891-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007891-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/urn:x-wiley:14651858:media:CD007891:CD007891-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_t/tCD007891-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 5 Pneumonia." data-id="CD007891-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 5 Pneumonia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/references#CD007891-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007891-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/urn:x-wiley:14651858:media:CD007891:CD007891-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_t/tCD007891-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 6 Quality of life." data-id="CD007891-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 6 Quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/references#CD007891-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007891-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/urn:x-wiley:14651858:media:CD007891:CD007891-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_t/tCD007891-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 7 FEV1 (litres)." data-id="CD007891-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 7 FEV<sub>1</sub> (litres). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/references#CD007891-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007891-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/urn:x-wiley:14651858:media:CD007891:CD007891-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_t/tCD007891-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 8 Serious adverse events (non‐fatal)." data-id="CD007891-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 8 Serious adverse events (non‐fatal). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/references#CD007891-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007891-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/urn:x-wiley:14651858:media:CD007891:CD007891-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_t/tCD007891-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 9 Adverse events." data-id="CD007891-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 9 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/references#CD007891-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007891-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/urn:x-wiley:14651858:media:CD007891:CD007891-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_t/tCD007891-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 10 Withdrawal." data-id="CD007891-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Fluticasone/salmeterol (FPS) versus tiotropium (TIO), Outcome 10 Withdrawal.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/references#CD007891-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/media/CDSR/CD007891/image_n/nCD007891-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD007891-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Differences in the reported cases of pneumonia in the INSPIRE trial</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonias recorded in patients treated with fluticasone/salmeterol</b> </p> <p><b>Number (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonias recorded in patients treated with tiotropium</b> </p> <p><b>Number (%)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Most frequent adverse effects on ITT population*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (3)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (3)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fatal serious adverse events*</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (&lt; 1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events including pneumonia, lobar pneumonia and bronchopneumonia**</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50 (8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (4)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>*Reported in SCO40035.</p> <p>**Reported in Wedzicha 2008.</p> <p>ITT: intention‐to‐treat</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Differences in the reported cases of pneumonia in the INSPIRE trial</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/full#CD007891-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007891-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Reasons for withdrawals from INSPIRE</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reason for withdrawal</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Fluticasone/salmeterol</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tiotropium</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrew consent</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lost to follow‐up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Protocol violation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Failed entry criteria</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>COPD exacerbation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Lack of efficacy</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Other</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232 (35.3%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>279 (42.0%)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>COPD: chronic obstructive pulmonary disease</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Reasons for withdrawals from INSPIRE</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/full#CD007891-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007891-tbl-0003"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Proportion of participants developing pneumonia</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia on FPS</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia on comparison treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial duration, weeks</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia on FPS per 52 weeks</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pneumonia on comparison per 52 weeks</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naninni 2007a<sup>†</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325/2673 (12%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194/2556 (8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TORCH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303/1546 (20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164/1544 (11%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Naninni 2012<sup>†</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>447/5922</p> <p>(7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>280/5154 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92*</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>TORCH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>303/1546 (20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LABA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205/1542 (13%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.3%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>INSPIRE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50/658 (8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tiotropium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/665 (4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>†</sup>Includes data from TORCH. </p> <p>*Weighted mean trial duration.</p> <p>FPS: fluticasone/salmeterol <br/> LABA: long‐acting beta<sub>2</sub>‐agonist </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Proportion of participants developing pneumonia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/full#CD007891-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007891-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fluticasone/salmeterol (FPS) versus tiotropium (TIO)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality (all‐cause) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Hospital admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Hospital admissions all‐cause</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Hospital admissions resulting from exacerbations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Exacerbations (all‐cause): number of patients experiencing one or more exacerbations over two years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Exacerbations (mean number of exacerbations per patient per year) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Exacerbations (all‐cause)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Exacerbations requiring oral corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Exacerbations requiring antibiotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pneumonia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 32 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 104 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 FEV<sub>1</sub> (litres) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 FEV1 at short time frame (3 to 12 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 FEV1 at 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Serious adverse events (non‐fatal) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Withdrawal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Total number of subjects withdrawn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Due to adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Due to lack of efficacy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fluticasone/salmeterol (FPS) versus tiotropium (TIO)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007891.pub3/references#CD007891-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007891.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007891-note-0001">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007891-note-0007">فارسی</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007891\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007891\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007891\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007891\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007891\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007891.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007891.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007891.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007891.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007891.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715236903"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007891.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715236907"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007891.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d822d6a8bf446',t:'MTc0MDcxNTIzNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 